Venous thromboembolism in patients with HIV/AIDS: a case-control study.

Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
JAIDS Journal of Acquired Immune Deficiency Syndromes (Impact Factor: 4.39). 07/2008; 48(3):310-4. DOI: 10.1097/QAI.0b013e318163bd70
Source: PubMed

ABSTRACT Retrospective cohort studies of HIV-infected patients suggest an incidence of venous thromboembolism (VTE) of 1% to 2%, which is 10 times that expected among people without HIV. We investigated the prevalence of established risk factors for VTE in this population and explored novel risk factors.
We conducted a case-control study using patients in the Johns Hopkins University AIDS Service cohort. We used conditional logistic regression and paired t tests to test for covariates significantly associated with VTE.
We identified 160 patients with VTE diagnosed radiologically or with a clinical course consistent with VTE; 23% of the cases of VTE were diagnosed in hospitalized patients. The incidence of VTE was approximately 0.5% per patient-year. Patients with VTE and control patients did not differ by gender, but black patients were overrepresented among those with VTE (odds ratio [OR]=1.9, 95% confidence interval [CI]: 1.11 to 3.08) and patients with VTE were older than controls (mean: 39 vs. 37 years; P=0.001). Patients with VTE had lower CD4 counts (229 vs. 362 cells/mm; P<0.0001), higher HIV RNA titers (120,254 vs. 71,262 copies/mL; P=0.013), and lower hemoglobin concentrations (11.4 vs. 12.7 g/dL; P<0.0001) preceding the event than those without VTE. The use of highly active antiretroviral therapy was not associated with VTE. In multivariate analyses, independent risks for VTE were age, hospitalization in the past 3 months (OR=13, 95% CI: 6.4 to 27), central venous catheter use in the past 3 months (OR=6.0, 95% CI: 2.3 to 16), and a CD4 count<500 cells/mm (OR=3.0, 95% CI: 1.2 to 7.8).
The incidence of VTE in our cohort is similar to that reported in other cohorts of patients with HIV. Recent hospitalization was the risk factor most strongly associated with VTE.

  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Chronic activation of the immune system and related tissues is a pervasive characteristic of HIV infection at all stages of disease progression. It is well established that measures of immune activation are strong independent predictors of CD4+ T cell depletion and immune suppression. Mechanistic insights of its role in immune pathogenesis are emerging, which point to a direct participation of chronic activation in the development of immune suppression, as well as in other inflammation-related pathologies that accompany HIV infection. Extensive further research has found that activation spans a broad range of cells and functions of the immune system, and is present at all stages of HIV disease, even under control of viral replication. Important advances in the mechanisms underlying immune activation have been made in the last years, revealing diverse triggers ranging from HIV itself to toll-like receptor ligands. Of particular importance, the passage of bacterial products to the blood of HIV-infected patients is a cause of immune activation that has greatly influenced the study and management of HIV pathogenesis. This chapter reviews the evidence for the central pathogenic role of activation, the mechanisms that cause it, its role in immunesuppression, and the consequences of chronic inflammation. Attention is made on non-AIDS-defining illnesses, which have emerged with the control of immunodeficiency by highly active antiretroviral therapy. Recent findings support current efforts to control activation/inflammation as part of effective treatment of HIV infection.
    Molecular Aspects of Inflammation, 1 edited by Leonor Pérez-Martínez, Gustavo Pedraza-Alva, Eduardo Ferat-Osorio, 01/2013: chapter 6: pages 99-140; Research Signpost., ISBN: 978-81-308-0528-3
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Venous thromboembolism has also become a major health concern in sub-saharian Africa. Studies addressing at this issue are rare in Cameroon. Thus, the case reported here presents singular characteristics: its clinical form, phlegmasia cerulea dolens, a severe but uncommon complication of venous thromboembolism; and its infrequent recorded triggering factor, HIV-AIDS.
    01/2014; 19:282. DOI:10.11604/pamj.2014.19.282.4385
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Some surgeons believe that internal fixation of fractures carries too high a risk of infection in low-income countries (LICs) to merit its use there. However, there have been too few studies from LICs with sufficient follow-up to support this belief. We first wanted to determine whether complete follow-up could be achieved in an LIC, and secondly, we wanted to find the true microbial infection rate at our hospital and to examine the influence of HIV infection and lack of follow-up on outcomes. Patients and methods 137 patients with 141 femoral fractures that were treated with intramedullary (IM) nailing were included. We compared outcomes in patients who returned for scheduled follow-up and patients who did not return but who could be contacted by phone or visited in their home village. Results 79 patients returned for follow-up as scheduled; 29 of the remaining patients were reached by phone or outreach visits, giving a total follow-up rate of 79%. 7 patients (5%) had a deep postoperative infection. All of them returned for scheduled follow-up. There were no infections in patients who did not return for follow-up, as compared to 8 of 83 nails in the group that did return as scheduled (p = 0.1). 2 deaths occurred in HIV-positive patients (2/23), while no HIV-negative patients (0/105) died less than 30 days after surgery (p = 0.03). Interpretation We found an acceptable infection rate. The risk of infection should not be used as an argument against IM nailing of femoral fractures in LICs. Many patients in Malawi did not return for follow-up because they had no complaints concerning the fracture. There was an increased postoperative mortality rate in HIV-positive patients.

Full-text (2 Sources)

Available from
May 22, 2014